All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

  TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer.   View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Does interim fluorodeoxyglucose-PET have predictive value?

Nov 16, 2016


Hugo Adams and Thomas Kwee, based in the Netherlands, recently wrote a correspondence in the Journal of Clinical Oncology, Oct 2016, in response to an article by Press et al. who presented the results of a US intergroup study that used interim FDG-PET imaging to decide whether or not to keep stage III-IV HL patients on ABVD or switch them to eBEACOPP.

Highlights:

  • 358 patients enrolled, 336 evaluable
  • PET scan after two ABVD cycles
  • Deauville score 1–3 = pts received 4 more cycles ABVD
  • Deauville score 4–5 = pts switched to 6 cycles eBEACOPP
  • 82% pts were PET-negative so stayed on ABVD, 18% were PET-positive and were switched to eBEACOPP
  • 2-year PFS estimate: PET-neg = 82%, PET-pos = 64%

One of the main issues with the study that Adams & Kwee present is that no control arm was used to compare against standard ABVD treatment. Furthermore, Adams & Kwee detailed a meta-analysis that did not support Press et al.’s claim that positive interim FDG-PET is associated with very poor prognosis. Additionally, Adams & Kwee state that follow-up FDG-PET has a high false-positive rate, but the authors did not report the histopathological confirmation of disease, and current PET techniques have poor resolution resulting in the possibility that small lymphocytic deposits may be missed. Adam & Kwee also state that using a more intense treatment option is only justified in cases where there is a proven significant difference in PFS and OS, which was not demonstrated in the paper. In conclusion, Adams & Kwee state that in patients with advanced HL, interim FDG-PET may not be as useful in improving outcomes as Press et al.suggest, and more work is needed to confirm any potential.

References

Your opinion matters

Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?